Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Nurix Therapeutics (NRIX) Operating Margin: 2019-2025

Historic Operating Margin for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -1,157.65%.

  • Nurix Therapeutics' Operating Margin fell 72382.00% to -1,157.65% in Q3 2025 from the same period last year, while for Aug 2025 it was -319.32%, marking a year-over-year increase of 2398.00%. This contributed to the annual value of -390.52% for FY2024, which is 18911.00% down from last year.
  • As of Q3 2025, Nurix Therapeutics' Operating Margin stood at -1,157.65%, which was down 955.45% from -109.68% recorded in Q2 2025.
  • Nurix Therapeutics' 5-year Operating Margin high stood at -87.25% for Q2 2023, and its period low was -1,157.65% during Q3 2025.
  • Over the past 3 years, Nurix Therapeutics' median Operating Margin value was -338.60% (recorded in 2023), while the average stood at -376.75%.
  • Its Operating Margin has fluctuated over the past 5 years, first spiked by 41,877bps in 2023, then tumbled by 72,382bps in 2025.
  • Over the past 5 years, Nurix Therapeutics' Operating Margin (Quarterly) stood at -513.16% in 2021, then slumped by 20,467bps to -717.82% in 2022, then spiked by 41,877bps to -299.06% in 2023, then crashed by 18,767bps to -486.73% in 2024, then tumbled by 72,382bps to -1,157.65% in 2025.
  • Its last three reported values are -1,157.65% in Q3 2025, -109.68% for Q2 2025, and -340.67% during Q1 2025.